Morgan Stanley Raises Cooper Companies (NASDAQ:COO) Price Target to $83.00

Cooper Companies (NASDAQ:COO) had its price objective raised by analysts at Morgan Stanley from $76.00 to $83.00 in a report issued on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the medical device company’s stock. Morgan Stanley’s price target suggests a potential upside of 5.72% from the company’s current price.

COO has been the topic of a number of other reports. Robert W. Baird raised their price target on Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Cooper Companies in a research report on Monday, December 1st. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research report on Friday. Wells Fargo & Company upped their price target on shares of Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, December 5th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.15.

Cooper Companies Stock Up 0.6%

Cooper Companies stock opened at $78.51 on Monday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. Cooper Companies has a one year low of $61.78 and a one year high of $100.47. The company has a 50-day simple moving average of $72.70 and a 200-day simple moving average of $71.60. The firm has a market capitalization of $15.61 billion, a P/E ratio of 41.76, a P/E/G ratio of 2.23 and a beta of 1.05.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the business posted $1.04 EPS. Cooper Companies’s revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, equities analysts expect that Cooper Companies will post 3.98 earnings per share for the current year.

Cooper Companies announced that its Board of Directors has approved a share repurchase plan on Wednesday, September 17th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical device company to reacquire up to 15.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Cooper Companies

In related news, Director Lawrence Erik Kurzius bought 2,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were acquired at an average cost of $68.39 per share, for a total transaction of $136,780.00. Following the acquisition, the director directly owned 5,777 shares of the company’s stock, valued at $395,089.03. The trade was a 52.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cooper Companies

Several institutional investors and hedge funds have recently bought and sold shares of the business. Zions Bancorporation National Association UT acquired a new stake in shares of Cooper Companies in the first quarter worth $33,000. Bell Investment Advisors Inc lifted its position in Cooper Companies by 106.3% during the 3rd quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after acquiring an additional 219 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in Cooper Companies during the first quarter valued at about $40,000. J.Safra Asset Management Corp grew its position in shares of Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 340 shares during the last quarter. Finally, CYBER HORNET ETFs LLC bought a new position in shares of Cooper Companies in the second quarter worth about $36,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.